Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

今日，礼来公司（Eli Lilly and ...

Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...